Affordable blood tests for managing lung cancer treatment
Rapid and affordable magneto-nanosensors for ctDNA-guided lung cancer management
This study is testing a quick and affordable blood test that looks for specific genetic changes in patients with non-small cell lung cancer to help doctors choose the best treatment for them and keep track of how well it’s working.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10888192 on NIH RePORTER |
What this research studies
This research focuses on developing a rapid and cost-effective blood test that detects circulating tumor DNA (ctDNA) to guide treatment decisions for patients with non-small cell lung cancer (NSCLC). By using advanced magneto-nanosensor technology, the study aims to identify specific genetic mutations that can inform targeted therapy selection and monitor treatment response. Patients will have their blood samples analyzed to determine the presence of mutations, allowing for timely adjustments in therapy based on their individual needs. The goal is to improve patient outcomes by ensuring that therapy is tailored to the genetic profile of their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who are undergoing or considering targeted therapy.
Not a fit: Patients with lung cancer who are not eligible for targeted therapies or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for lung cancer patients, potentially improving survival rates.
How similar studies have performed: Previous research has shown promising results with similar blood-based tests for cancer management, indicating a strong potential for success in this approach.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Wang, Shan X. — Stanford University
- Study coordinator: Wang, Shan X.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.